Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NETSTREIT Corp. (NTST)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Imara Corp (IMRA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

Imara is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Their pipeline is built on the differentiated therapeutic potential of their initial product candidate, IMR-687, which is an oral, once-a-day, highly selective, potent small molecule inhibitor of PDE9 in development for sickle cell disease and beta-thalassemia. Sickle cell disease and beta-thalassemia have limited treatment options and are both characterized by severe symptoms and effects and reduced life expectancy.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Rahul D. Ballal Michael P. Gray
Employees Founded
20 2016

Contacts

Address: 116 Huntington Avenue, 6th Floor, Boston, MA 02116, US

Telephone: (617) 206-2020

Web page: http://www.imaratx.com

IPO information

Expected Date 3/12/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $265.2
Revenues (MM) $0
Net Income (Loss) (MM) $-23.5

Voting

What do you think will happen with the IMRA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 4.45
Shares Revised (MM) 4.7
Expected offer amount (MM) $75.65
Realized offer amount(MM) $75.2
Underwriters
Morgan Stanley/ Citigroup/ SVB Leerink
CO-Managers
-

Sector: Healthcare

Tweets about $IMRA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats